Bailard
ZVRA icon

Bailard’s Zevra Therapeutics ZVRA Stock Holding History

Bailard’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$161K Hold
14,700
– – ﹤0.01% 730
2026
Q2 		$211K Hold
14,700
– – ﹤0.01% 727
2026
Q1 		$137K Buy
14,700
+1,800
+14% +$16.2K ﹤0.01% 712
2025
Q4 		$116K Buy
+12,900
New +$122K ﹤0.01% 735

Other funds holding ZVRA

RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $263M AUM 26.23% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $451M AUM 22.13% 1-Year Est. Return
IFG Advisors
IFG Advisors St. Louis, Missouri $730M AUM 19.37% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Bailard's ZVRA Position: Q3 2026 in Review

Bailard held its Zevra Therapeutics (ZVRA) position steady in Q3 2026 at 14,700 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #730.

Bailard first reported a position in ZVRA in Q4 2025 and has held it in 4 quarters since. The position peaked at $211K in Q2 2026. 14 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.

  • Bailard held 14,700 shares of Zevra Therapeutics worth $161K as of Q3 2026.
  • Bailard left its Zevra Therapeutics share count unchanged in Q3 2026.
  • Zevra Therapeutics made up ﹤0.01% of Bailard's portfolio in Q3 2026, its #730 holding.
  • Bailard first reported a position in Zevra Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Bailard's Zevra Therapeutics position peaked at $211K in Q2 2026.
  • 14 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.